Literature DB >> 2454267

Antibody-mediated activation of T cell clones as a method for screening hybridomas producing antibodies to the T cell receptor.

O Kanagawa1.   

Abstract

In this study, supernatants (SN) of hybridomas established by fusing P3X63.Ag8.653 to spleen cells from C57L mice (V beta 8 family of T cell receptor (TcR) gene negative) immunized with the H-Y specific V beta 8 allotype positive helper T cell (HTL) clone OI6 were screened for the capacity to activate cloned T cells in the absence of interacting stimulator cells. In the first assay, SNs were mixed with V beta 8+ H-Y specific CTL OH2 and 51Cr-labelled non-specific B lymphoma (L10.A). In this system, antibodies (Ab) which can bind to L10.A by Fc-Fc receptor interaction and recognize TcR can facilitate lysis of L10.A target cells by OH2 CTL. In the second assay, OI6 clone cells were cultured in microtiter well, previously coated with hybridoma supernatants (SN). In this assay, Ab recognizing OI6 TcR complex and bound to plastic plates can stimulate OI6 cells to proliferate in the absence of stimulator cells. Using these two screening methods, nine hybridomas were established. Analysis of these hybridoma SN using surface staining, inhibition of T cell function and immunoprecipitation of radiolabelled surface molecules followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS/PAGE) showed that five Ab were directed to the allotypic determinant (V beta 8) of TcR and four Ab were specific to the clonotypic determinant of OI6 TcR. These results suggest that this Ab-mediated activation of T cell clone can be used for the screening of hybridomas secreting anti-TcR Ab and the immunogenicity of OI6 clonotypic determinants is similar to that of the V beta 8 allotypic determinant even in strains which do not express the V beta 8 TcR allotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454267     DOI: 10.1016/0022-1759(88)90100-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant.

Authors:  M E Wallace; R Keating; W R Heath; F R Carbone
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Predominant T-cell receptor Vbeta usage of intraepithelial lymphocytes during the immune response to enteric reovirus infection.

Authors:  D Chen; F Lee; J J Cebra; D H Rubin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4.

Authors:  T Yoshimoto; A Bendelac; J Hu-Li; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

4.  The MHC molecule I-E is necessary but not sufficient for the clonal deletion of V beta 11-bearing T cells.

Authors:  J Bill; O Kanagawa; D L Woodland; E Palmer
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

5.  Inhibition of MHC class II-restricted T cell response by Lyt-2 alloantigen.

Authors:  O Kanagawa; R Maki
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

6.  T cell receptor beta chain lacking the large solvent-exposed Cbeta FG loop supports normal alpha/beta T cell development and function in transgenic mice.

Authors:  S Degermann; G Sollami; K Karjalainen
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

7.  Inactivation of human immunodeficiency virus (HIV)-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism?

Authors:  H Takahashi; Y Nakagawa; G R Leggatt; Y Ishida; T Saito; K Yokomuro; J A Berzofsky
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

8.  T cell and non-T cell compartments can independently determine resistance to Leishmania major.

Authors:  A H Shankar; R G Titus
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.